The CMTA’s STAR Research Initiative | Charcot-Marie-Tooth Association

The CMTA’s STAR Research Initiative

CMTA Awards $1 Million for STAR Research Projects – Read more …


STAR, the CMTA’s research initiative, was created with one goal: to find treatments to slow, stop or reverse the progression of CMT. Working with investigators and scientists chosen from an international body of the world’s most accomplished medical pioneers, STAR is leading CMT research. The STAR program’s success is due to the willingness of scientists working in their areas of expertise to come together as a team to advance CMT research, sharing and communicating ideas, discoveries and findings. The CMTA also works with the pharmaceutical, biotechnology and research service industries, non-profit research organizations and the National Institutes of Health. These relationships are a critical part of the STAR initiative’s goal of rapidly delivering therapies to CMT patients. The integrated team of top scientists and industry partners working together toward a common goal is what sets the STAR program apart and what drives its remarkable success.

CMT1A Research Breakthrough

CMT1A Research Breakthrough!

Scientists at Ionis Pharmaceuticals, in collaboration with the Charcot-Marie-Tooth Association, have identified a promising early-stage therapeutic approach with antisense technology for CMT Type 1A (CMT1A), the most common form of the disease, accounting for half of all cases. Read more …